



Papar No.5. 6

Sheet 1 of 2

							
	FORM PTO-1449 U.S. D	EPARTMENT O	F COMMERCE	ATTY. DOCKET NO.	SERIAL	==== NO	
	PATENT AND TRADEM		MARK OFFICE	1038-1003 MIS:bh	09/462,816		
	INICODMATICAL					8	
ı	INFORMATION	DISCLOSURE	}		ł	Ţ.	
ı	STATEMENT BY	ARBLICAN					٠,
ı	FEB 1 1 mg (s)		ľ		L	122	
			į į	APPLICANT: Xiaomao Li et al			
	PATE	2000		FILING DATE:	GROUP:	*****	.]
Щ					635	<u>155</u>	l
U.S. PATENT DOCUMENTS						w	

(= = = = .			V
	*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
ΒM	RW	5,020,896	April/1997	Herrmann; John E. et al.	435	320.1	April-20, 1997
							7 (7111 20) 10074
ŀ							
Ĺ							

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	1	McIntosh K., Canock, R.M. In: Fields B.N. Knine DM editors Virology New York D.				
' Heilman, C.A., J. Infect. Dis. 1990, 161: 402 to 406.						
4* Murphy, B. R. et al, 1994, Virus Res. 32: 13-36.						
5 L'évine, S., Kleiber-France, R., and Paradiso, P.R. (1987) J. Gen. Virol. 69, 25						
	6 -	Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, F. (1985) J. Infect. Dis. 151, 626-633.				
	7 :	Johnson et al., J. Virol 1987, 61: 3163-3166				
	8 Crowe, J.E., Vaccine 1995, 13: 415-421 9 Kapikian, A.Z. et al 1969, Am. J. Epidemiol. 89: 405-421					
10 Kim, H.W., et al 1969 Am. J. Epidemiol. 89: 422-434.						
	Murphy, B.R. et al 1986 J. Clin. Microbiol. 24. 197-202.					
12 Vaux-Peretz, F. et al 1992 Vaccine 10: 113-118.						
	13	Openshaw, P.J. 1995 Springer-Semin Immunopathol. 17: 187-201.				
	14	Alwan et al 1994 J. Exp. Med. 179:81-89.				
<u> </u>	15 3 Graham, B.S. 1995 Am. J. Respir, Crit. Care Med. 152:563-6 563-566					
XAMINE	$R: B_{\Lambda}$	n Herry DATE CONSIDERED: 17/10/01				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

^{*} Will follow shortly





FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: \1038-1003 MIS:bh

SERIAL NO. : 09/462,816

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

PARE 1 1 2000

PPLICANT: Xiaomao Li et al

FILING DATE:

GROUP:

FOREIGN PATENT DOCUMENTS

6 7	ļ <u>, , , , , , , , , , , , , , , , , , ,</u>	DOCUMENT NO.	. DATE	COUNTRY	CLASS	SUBCL.	TRANS	SLATION
132	16	WO 90/11092	04/Oct/99	THE WERD			YES	NO
BW	17	WO 94/21797	29/3ept/94	101 to 210				110
		OTHER DO	CUMENTS (Includin	g Author, Title, Date, Pe	ertinent Page	es. Etc.)		L
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 18 Ulmer, Current Opinion, Invest Drugs, 1993, 2. 983-989							
	19 Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L. Nivel, Acids, Print 4001, 10:							
	20 * Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307 11314							
	21	Tang et al., Nature						
<i></i>	22 1	Furth et al. Analyti	cal Biochemistry,	1992, 205: 365-368			~	
	23	Davis et al., Vacci						- 1-3
	23 Graham, B.S.; Perkins M.D.; Wright, P.F. and Karzon, D.T. J. Mod. Virol. 1988 26; 153-162.							162
	25 Du, R.P. et al. 1994, Bio. Technology 12. 813-818 26 Prince, G.A. et al., 1978, Ame. J. Pathol. 93: 771 790: 73, 75, 77, 79, 81,75, 87, 87							
	27 Stott, E. J. Et al, Journal of Virology, (1986 Nov) 60 (2) 607-13 28 Hsu, K. H. et al Journal of Infectious Diseases. (1992 Oct) 108(4) 769-75 29 Stott, E. J. Et al, Journal of Virology. (1987 Dec) 61(12) 3855-61 30 Elango, N. et al. Proceedings of the National Academy of Sciences of the United States of America, (1986 Mar) 83(6) 1906-10							
								of
	31 Roberts, S.R. et al, Journal of Virology, (1994 Jul) 68(7) 4538-46 32 Nguyen, T. N. et al, Journal of Biotechnology, (1995 Oct.16) 42(3) 207-19							
	Wathen, M. W. et al, Journal of General Virology, (1989 Oct) 70 (PT-10) 2625-35							
	34 : Schrijver, R. S. Et al, Vaccine, vol.16, no.2-3, 2 January 1998, page 130-134							
	35 Johnson, T. R. et al. Journal of Virology, (1998 Apr) 72(4) 2871-80							
EXAMINER:	3 drai	2 n Ateman	DA	TE CONSIDERED: 7	(11)/1) /		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.